Targeted α-therapy using astatine (²¹¹At)-labeled PSMA1, 5, and 6: a preclinical evaluation as a novel compound.

ABSTRACT:

Purpose

Targeted α-therapy (TAT) for prostate-specific membrane antigen (PSMA) is a promising treatment for metastatic castration-resistant prostate cancer (CRPC). Astatine is an α-emitter (half-life=7.2 h) that can be produced by a 30-MeV cyclotron. This study evaluated the treatment effect of ²¹¹At-labeled PSMA compounds in mouse xenograft models.

Methods

Tumor xenograft models were established by subcutaneous transplantation of human prostate cancer cells (LNCaP) in NOD/SCID mouse. [²¹¹At]PSMA1, [²¹¹At]PSMA5, or [²¹¹At]PSMA6 was administered to LNCaP xenograft mice to evaluate biodistribution at 3 and 24 h. The treatment effect was evaluated by administering [²¹¹At]PSMA1 (0.40 ± 0.07 MBq), [²¹¹At]PSMA5 (0.3

SUBMITTER: Watabe T 

PROVIDER: S-EPMC9852121 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature